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
         
     إ      
 302008 –
 ±    1632     15  15        
                3.42 ± 21.23 
 
 2
 
 6 > 90 > 2 1.73 90 < 
 %1 < 2.5 >
 10 22 < 2% 6.7
% 23.3 0.85 <%
% 76.7 23  0.95 < 0.95 0.85
% 3.3 1.0 < 
 < 1.5% 96.7 29 1.5 1.0
% 80 24  1.4
 (r = 0.904, P < 0.001) 

 

 :مفتاح الكلمات
aBStract: Objectives: There are limited data concerning the assessment of renal function in beta-thalassaemia 
major, with no study of such involvement in Omani patients. The objective of this study was to establish the 
pattern of renal glomerular and tubular function using traditional and specific laboratory tests in patients with 
beta-thalassaemia major. Methods: This cross-sectional study, from January–July 2008, included 30 patients of 
the Thalassaemia Clinic at the Royal Hospital, Oman, with transfusion-dependent homozygous beta-thalassaemia 
major. They included 15 males and 15 females, aged 16-32 years with mean ± standard deviation of 21.23 ± 3.42 
years. The medical records were reviewed and renal function states assessed as follows: serum creatinine, estimated 
glomerular filtration rate (eGFR); urea; phosphate, fractional excretion of filtered sodium (FENa); urine albumin: 
creatinine index; urine ß2-microglobulin:creatinine index; tubular reabsorption of phosphate (TRP), and tubular 
maximum phosphate reabsorption (TmP)/GFR. Results: All patients had eGFR >90 ml/min/1.73m2; serum 
creatinine <90 µmol/L; serum urea <6.0 mmol/L, and urine albumin:creatinine <2.5 mg/mmol. Only 2 (6.7%) 
patients had FENa >1% and 3 (10.0%) patients had urine ß2-microglobulin: creatinine >22 µg/mmol. All patients 
had TRP >0.85, of whom seven (23.3%) patients had values within the range of 0.85-0.95 and 23 (76.7%) had values 
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Haemoglobinopathies are a common medical problem worldwide including in Oman.1 A recent prospective neonatal 
screening programme in two major cities of 
Oman, which included consecutive cord blood 
samples from a total of 7,837 neonates, revealed 
that the overall incidence of alpha-thalassaemia 
(alpha-thal) was 48.5%. Beta-globin-related 
abnormalities accounted for 9.5% of the samples 
(4.8% sickle cell trait, 2.6% beta-thalassaemia trait, 
0.9% haemoglobin (Hb) E trait, 0.8% Hb D trait, 
0.08% Hb C trait, 0.3% sickle cell disease and 0.08% 
homozygous beta-thalassaemia).2 Also, data from 
an earlier community-based survey of the most 
common genetic blood disorders among Omani 
children reported a prevalence rate of 2% for beta-
thalassaemia trait, 0.07% for beta-thalassaemia 
major, 6% for sickle cell trait and 0.2% for sickle cell 
disease.3 Comparable data has also been reported 
from Gulf Cooperation Council states and other 
neighbouring countries.4,5,6,7
Beta-thalassaemia major is an inherited 
monogenic disorder that was first described 
in 1925 by Cooley and Lee.8 It is caused by a 
mutation at the ß-globin gene locus resulting in 
persistence of α-globin chain that is precipitated 
within the erythroid precursors in the bone 
marrow associated with severe dyserythropoeitic 
anaemia.9 The combination of early diagnosis, 
improvement in monitoring complications and 
advances in supportive therapy has enabled 
patients with thalassaemia major to have improved 
life expectancy.10 The cornerstone of management 
is life-long blood transfusion with frequent iron 
chelation therapy to minimise the deleterious effect 
of chronic iron deposition and its accumulation 
in tissues.9 Despite this, these patients are prone 
to long-term organ dysfunction particularly the 
cardiovascular, hepato-biliary, endocrine and 
skeletal systems.11 The renal system, particularly 
the kidneys, is an important functional unit that 
is exposed to the pathophysiological changes as 
well as the burden of iron deposition and chelation 
therapy in beta-thalassaemia. However, it appears 
that there is limited data available concerning renal 
involvement in this disease, and no such data is 
available for patients with beta-thalassaemia in 
Oman.
The objective of this study was to evaluate the 
degree of renal dysfunction, both glomerular and 
tubular, using traditional and specific laboratory 
tests of renal function in adult Omani patients 
with transfusion-dependent homozygous beta-
thalassaemia major at the Royal Hospital, Oman.
ADVANCES IN KNOWLEDGE
1. The cornerstone in the management of patients with beta-thalassaemia major is life-long blood transfusion with frequent iron chelation 
therapy. Despite this, these patients are prone to long-term organ dysfunction particularly in their cardiovascular, hepato-biliary, 
endocrine and skeletal systems. The renal system, particularly the kidneys, also undergoes pathophysiological changes and may be 
affected by the burden of iron and the chelation therapy. This is the first study of the assessment of laboratory-based renal function tests 
in patients with beta-thalassaemia major in Oman.
2. Glomerular tests are usually within the reference ranges, while alteration in certain tubular tests (such as raised TRP and TmP/GFR) 
may reflect an upward trend in serum phosphate and, as a consequence, in increasing renal phosphate reabsorption. Otherwise, renal 
function appeared to be well preserved with no overt renal disease. 
APPLICATION TO PATIENT CARE
1. This study helps health care professionals to select and interpret renal function tests in patients with beta-thalassaemia major using 
glomerular indicators (eGFR, serum creatinine, urine microalbumin) and tubular indicators (FENa, ß2-microglobulinuria, TRP and 
TmP/GFR). 
>0.95. Also, all patients had TmP/GFR >1.0 mmol/L, of whom only one (3.3%) patient had TmP/GFR of 1.0–1.5, 
and 29 (96.7%) patients had TmP/GFR >1.5 mmol/L. Finally, 24 (80%) patients had serum phosphate >1.4 mmol/L. 
Linear regression revealed a highly significant correlation between serum phosphate and TmP/GFR (r = 0.904, P 
< 0.001). Conclusion: Renal function, glomerular and tubular, appears to be well preserved in beta-thalassaemia 
major. Almost all renal function indicators were within the recommended ranges. Raised TmP/GFR and TRP 
were noted in the majority of patients, reflecting an up-trend in serum phosphate and therefore increasing renal 
phosphate reabsorption.
Keywords: Beta-thalassaemia; Glomerular; Tubular; Renal function; Oman
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Methods
This cross-sectional study was conducted during a 
six months period (1 January to 31 July 2008) and 
covered adult Omani patients with transfusion-
dependent homozygous beta-thalassaemia major 
registered with the Thalassaemia Clinic at the 
Royal Hospital, Oman. This is one of a number of 
thalassaemia clinics in Oman which together deal 
patients with this disease. The study included 30 
patients (15 male, 15 female), aged 16–32 years 
who were seen at the clinic at 3 monthly intervals. 
The diagnosis of homozygous thalassaemia 
was based on the characteristic haematological 
criteria (peripheral blood evaluation and 
haemoglobinopathy screening) at presentation or 
screening from the early years of life. 
The study protocol was a naturalistic observation, 
an integral part of routine clinical procedure 
through reviewing the medical records of these 
thalassaemic patients from the hospital computer 
records including the haematologists’ clinical review 
as well as results of laboratory investigations. The 
clinical haematologists are regularly consulted on 
the management of these patients which includes 
supervision of blood transfusion and chelation 
therapy, as well as monitoring of organ dysfunction 
due to predicted iron deposition in tissues. The 
patients had been regularly transfused every three 
weeks since the early years of life with packed red 
blood cells, and were regularly taking iron chelators 
such as desferrioxamine (40 mg/kg body weight) 
as subcutaneous infusions 5 days per week, and 
deferiprone (75 mg/kg body weight) tablets daily. 
For the laboratory investigations, blood 
samples were collected in the fasting state, and 
early morning urine specimens were provided 
from all the patients during their visits to the 
clinic. In addition to complete blood count and 
serum ferritin, different biochemical function 
profiles are regularly done to screen for any 
possible dysfunction. Evaluation of renal function 
is usually performed, together with other core 
function profile tests. The biochemical tests 
included: serum creatinine, and creatinine-based 
estimated glomerular filtration rate (eGFR); urea; 
phosphate as well as fractional excretion of filtered 
sodium (FENa); urine albumin: creatinine index 
(for microalbuminuria); urine ß2-microglobulin: 
creatinine index (for ß2-microglobulinuria); 
tubular reabsorption of phosphate (TRP), and 
tubular maximum phosphate reabsorption/GFR 
(TmP/GFR). All these parameters were measured 
in the Clinical Biochemistry Laboratory at the 
Royal Hospital. Creatinine was analysed by kinetic 
Jaffe reaction; urea and sodium by ion-selective 
electrodes; phosphate by molybdenum blue, and 
albumin by the immunoturbidemetric method (all 
from Synchron LX20, Beckman Coulter, Inc, CA, 
USA), and ß2-microglobulin by chemiluminescent 
microparticle immunoassay method on AXSym 
(Abbott, USA).12 Urinary ratios of microalbumin 
and ß2-microglobulin in relation to urine 
creatinine, as well as FENa were calculated.12 
The eGFR was calculated by the Modification of 
Diet in Renal Disease (MDRD) equation13 and 
TRP as well as TmP/GFR were calculated as 
recommended by Payne.14 The reference ranges 
for the concerned biochemical parameters were as 
follows: serum creatinine (female 40–90 µmol/L; 
male 50–100 µmol/L); eGFR (>90 ml/min/1.73m2); 
serum urea (3.0–6.0 mmol/L); serum phosphate 
(0.7-1.4 mmol/L); FENa (<1%); urine albumin: 
creatinine ratio (female < 3.5 mg/mmol, male < 2.5 
mg/mmol); urine ß2 microglobulin: creatinine ratio 
(<22 µg/mmol); TRP (0.85–0.95), and TmP/GFR 
(1.0–1.5 mmol/L). 
The results were analysed and numerical data 
presented as mean ± standard deviation (SD) and 
range. ANOVA (analysis of variance) was used to 
compare the differences in the means of results 
between the different groups. Pearson’s correlation 
coefficient was also used to compare between 
certain parameters where appropriate, which 
include serum phosphate and TmP/GFR. The 
statistical significance was assigned at P < 0.05.15  
Results
Thirty homozygous ß-thalassaemia patients 
(15 male, 15 female), aged 16-32 years, mean 
21.23 years, SD of ± 3.42, were evaluated in this 
study. The recommended cut-off for the studied 
renal function tests include: eGFR >90 ml/
min/1.73m2; serum creatinine <90 µmol/L 
(in females) and <100 µmol (in males); serum 
urea <6.0 mmol/L; serum phosphate <1.40 
mmol/; FENa <1.0 %; urine albumin: creatinine 
<3.5 mg/mmol (in females) and <2.5 mg/mmol 
(in males); urine ß2micglobulin: creatinine 
Indicators of Renal Glomerular and tubular Functions in Patietns with Beta-Thalassaemia Major 
A cross sectional study at the Royal Hospital, Oman
72 | SQU Medical Journal, February 2011, Volume 11, Issue 1
<22 µg/mmol; TRP 0.85–0.95, and TmP/GFR 
1.0–1.5 mmol/L. 
The results of the renal function tests, glomerular 
and tubular, are shown in Table 1. For eGFR, and due 
to the possible effect of imprecision and analytical 
bias in creatinine assays at concentrations within 
the reference range, it has been recommended to 
report eGFR values higher than 90 ml/min/1.73m2 
as >90 ml/min/1.73m2 with no numerical value.16 
Hence, statistical data was not  applied for eGFR 
results when calculated eGFR >90 ml/min/1.73m2. 
All thirty patients had eGFR >90 ml/min/1.73m2; 
serum creatinine <90 µmol/L (all group median 
43, range 23–73 µmol/L); serum urea <6.0 mmol/L 
(median 3.3, range 1.3–5.6 mmol/L), and urine 
albumin: creatinine <2.5 mg/mmol (median 0.50, 
range 0.1–1.7 mg/mmol). Only two (6.7%) patients 
had FENa >1% (median 0.30, range 0.06–1.35%), and 
three (10%) patients had urine ß2-microglobulin: 
creatinine >22 µg/mmol (median 7.1, range 1.14–
60.4 µg/mmol). 
Concerning renal phosphate handling, all 
patients had TRP >0.85 (all group median 0.97, 
range 0.91–0.99), and TmP/GFR >1.0 mmol/L 
(median 2.01, range 1.15–4.48 mmol/L). Further 
characterisation of the results revealed that seven 
(23.3%) patients had TRP within the recommended 
reference range of 0.85–0.95 and 23 (76.7%) 
patients had values >0.95, with no patient having 
TRP <0.85. For TmP/GFR, only one (3.3%) patient 
had TmP/GFR within the reference range of 1.0–
1.5 mmol/L, and 29 (96.7%) patients had raised 
TmP/GFR >1.5 mmol/L; 13 (43.3%) patients had 
values 1.51–2.00 mmol/L, nine (30%) had values 
2.01–2.50 mmol/L, five (16.7%) had values 2.5–3.0 
mmol/L and two (6.7%) had values >3.0 mmol/L; 
no patient had TmP/GFR <1.0 mmol/L. Also, six 
(20%) and 24 (80%) patients had serum phosphate 
≤1.4 and >1.4 mmol/L respectively (median 1.66, 
range 1.10–3.14 mmol/L). A linear regression 
analysis revealed a highly significant correlation 
between serum phosphate and TmP/GFR (r = 
0.904, P <0.001), [Figure 1].
In order to compare the parameters of 
phosphate handling, the results were also assessed 
in relation to the endocrine complications that 
were previously reported and reviewed in these 
patients.17 The patients were grouped as those with 
≥ one endocrinopathy, n = 22; hypogonadism alone, 
n = 12; hypogonadism with diabetes mellitus, n = 
7; with primary hypoparathyroidism, n = 1; with 
hypoparathyroidism and diabetes mellitus, n = 1; and 
with hypoparathyroidism and hypothyroidism, n = 1, 
and those with no endocrinopathy, n = 8. A significant 
difference (P <0.005) was noted in TmP/GFR (2.456 
± 0.69 versus 1.818 ± 0.255 mmol/L) and in serum 
Table 1: Indicators of renal glomerular and tubular function tests in 30 patients with homozygous beta-thalassaemia.
Parameter Mean ± SD of Results No. and (%) of Patients
Normal Values Abnormal Values* Abnormal Values Normal Values
eGFR (ml/min/1.73m2) > 90 - 30 (100%) 0 (0.0%)
Serum creatinine (µmol/L)  44.4 ± 10 - 30 (100%) 0 (0.0%)
Serum urea (mmol/L) 3.4 ± 1.0 - 30 (100%) 0 (0.0%)
Serum phosphate (mmol/L) 1.33 ± 0.12 1.91 ± 0.39 6 (20%) 24 (80)
Urine albumin: creatinine 
(mg/mmoL)
0.69 ± 0.5 - 30 (100%) 0 (0.0%)
FENa (%) ** 0.35 ± 0.22 1.24 ± 0.14 28 (93.5%) 2 (6.7%)
Urine ß2.micglobulin: 
creatinine    (µg/mmoL) **
7.1 ± 4.9 39.3 ± 18.3 27 (90.0%) 3 (10.0%)
TRP *** 0.96 ± 0.02 - 30 (100%) 0 (0.0 %)
TmP/GFR *** (mmol/L) 2.28 ± 0.646 - 30 (100%) 0 (0.0 %)
Notes
* All patients marked as (-) had values within the reference ranges with no patient exceeded the cut-off for the renal function test 
** Only 2 patients had high results for FENa and 3 patients had high results for urine, B2.microglobulin: creatinine; statistical data are not presented 
as the number is low
***Abnormal values indicate high values for all parameters, except for TRP and TmP/GFR which are indicated by low values
Legend: eGFR = estimated glomerular filtration rate; FENa = fractional excretion of filtered sodium; TRP = tubular reabsorption of phosphate; TmP/
GFR =  tubular maximum phosphate reabsorption/glomerular filtration rate.
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phosphate (1.928 ± 0.42 versus 1.46 ± 0.18 mmol/L); 
however, no significant difference was noted in TRP 
(0.962 ± 0.021 versus 0.960 ± 0.025) in patients 
with and without endocrinopathy respectively. The 
three patients with primary hypoparathyroidism 
had the highest TmP/GFR values (4.48, 3.36, and 
2.32 mmol/L). No significant difference was noted 
in serum ferritin between these two groups (6480 ± 
3418.6 versus 5647 ± 3663 µg/L). 
Discussion
Patients with beta-thalassaemia major are prone to 
metabolic complications, including different organ 
dysfunction which can occur as single or multiple 
involvements. Although the actual mechanism is 
not definitive, the most likely explanation is related 
to anaemia and iron overload, in addition to lipid 
peroxidation, oxidative stress and free radical 
release.18
In this study, all 30 beta-thalassaemia major 
patients had normal glomerular renal function 
tests as indicated by their normal levels of eGFR 
>90 ml/min/1.73m2; serum creatinine <90 µmol/L; 
serum urea <6.0 mmol/L and urine albumin: 
creatinine <2.5 mg/mmol. Despite the increased 
iron deposition and the consequence of its possible 
oxidative stress on the renal parenchyma of these 
patients, many workers have also reported normal 
serum creatinine and creatinine clearance in 
patients with beta-thalassaemia major.19,20 The 
absence of microalbuminuria in our patients 
is another reflector of intact renal glomerular 
function. Microalbuminuria is an early indicator of 
nephropathy in patients at risk of developing kidney 
involvement, such as those with underlying chronic 
diseases including diabetes mellitus, hypertension 
or cardiovascular disease.21
In this study, almost all patients also had 
normal tubular renal function tests. This is 
indicated by the normal levels of FENa and urine 
ß2-microglobulin: creatinine, with only two (6.7%) 
patients having slightly raised FENa >1% and three 
(10%) patients with raised urine ß2-microglobulin: 
creatinine >22 µg/mmol; serum ß2-microglobulin 
was not measured in these three patients. Also, no 
patient had TRP <0.85 or TmP/GFR <1.0 mmol/L, 
which exclude the possibility of a renal tubular 
phosphate leak. Hence, all our patients had normal 
renal indicators for handling microalbumin and 
phosphate, with the vast majority of them having 
normal renal indicators for handling sodium 
and ß2-microglobulin. These are amongst the 
important tubular functions tests, which have 
almost excluded a significant impairment in tubular 
renal function in our patients’ series. Gosling 
reported an estimate that when there is complete 
failure of renal tubular absorption, there will be an 
approximately 1,800-fold normal increase in ß2-
microglobulin loss and 20-fold normal increase 
in urine albumin loss.22 In comparison with other 
studies, Aldudak et al. reported no significant 
Figure 1: Correlation between serum phosphate and tubular maximum phosphate reabsorption/glomerular filtration 
rate (TmP/GFR) in 30 homozygous beta-thalassaemia major patients.
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difference in creatinine clearance and FENa 
between thalassaemics and healthy controls.23 
Kalman et al. also reported no significant 
difference in many tubular function indicators 
that include fractional excretion of sodium, 
magnesium, uric acid as well as calcium, protein, 
glucose, urine ß-2.microglobulin, N-acetyl-ß-D-
glucosaminidase (NAG) levels and TRP in children 
with beta-thalassaemia major and thalassaemia 
intermedia.24 However, there are reports by other 
researchers who observed impairment in renal 
function when using other sensitive renal tubular 
function tests. Smolkin et al.25 reported normal 
creatinine clearance, FENa and TRP; however, 
urine NAG excretion was significantly raised in 
beta-thalassaemics, as also reported by Aldudak et 
al. 23 and Sumboonnnanonda et al.26, who observed 
increase in both urinary NAG and malondialdehyde 
(MDA) excretion. MDA is an indicator of lipid 
peroxidation.27 Hence anaemia and increased 
oxidative stress, possibly iron induced, may play 
a role in precipitating some degree of tubular 
dysfunction, which may be mild, and so can not 
be detected when using other tubular function 
indicators. 
In our study, 96.7% patients had TmP/GFR of 
>1.5 mmol/L and 76.7% patients had TRP values 
>0.95, indicating enhanced renal tubular phosphate 
reabsorption. This may be due to the raised 
phosphate level, due to the accelerated turnover of 
erythrocytes from the excess haemolysis in beta-
thalassaemia. This is supported by the observation 
that 80% of our thalassaemics had raised serum 
phosphate and the significant correlation 
(r = 0.904) observed between serum phosphate and 
TmP/GFR levels. This compares with other studies 
where some researchers revealed no change24,26 
while others observed some degree of altered TRP.23 
However, no data is available in the literature for 
comparing TmP/GFR as a renal tubular index in 
beta-thalassaemic patients, although this test is 
more representative of renal tubular handling of 
phosphate than TRP alone, but there is limited 
awareness about its importance.14 
Also, in this study significantly higher 
mean TmP/GFR and serum phosphate values 
were observed in beta-thalassaemics with 
endocrinopathies compared with those with no 
endocrinopathy. Hypogonadism, the most frequent 
endocrine disorder that was observed in 22 
(73.3%) thalassaemics in our series, appears to be 
the most likely underlying aetiology.17 The upward 
trend in TmP/GFR in these patients may be due to 
the decline in sex hormones (estrogens in women 
and androgens in men) as a consequence of 
impaired gonadal function resulting in a decline in 
the stimulating effect of sex hormones on calcitonin 
secretion, and accelerated bone resorption through 
inhibiting the formation of osteoclasts.28 Multiple 
pathways have been described for the inhibitory 
effect of estrogens and androgens on osteoclasts with 
calcitonin receptors and sex hormones have been 
demonstrated at multiple steps in the osteoclast 
lineage.29,30 Dundar et al. reported low calcitonin, 
osteocalcin, gonadal steroids, and pituitary 
hormones with high phosphate and N. telopeptide 
in beta-thalassaemic patients.31 In addition, other 
hormone deficiencies, such as parathyroid, thyroid 
and insulin, which are known to influence calcitonin 
secretion and skeletal protection as well as direct 
iron toxicity on osteoblasts, also contribute to the 
pathogenesis of altered bone metabolism in beta-
thalassaemia.32 The highest TmP/GFR values in our 
patients were observed in three beta-thalassaemics 
who had primary hypoparathyroidism in addition 
to hypogonadism. While the main function 
of the parathyroid hormone (PTH) is calcium 
homeostasis, it is also an important determinant 
of phosphate reabsorption, with TmP/GFR being 
increased in hypoparathyroidism and decreased in 
hyperparathyroidism.33 Normal or raised TmP/GFR 
may offer an advantage, as low values are associated 
with hypercalciuria, nephrocalcinosis and tubular 
proteinuria. This is presumably a result of direct 
tubular dysfunction, although it is controversial and 
may be difficult to prove.34,35,36 However, regardless 
of the underlying mechanism, in patients with renal 
tubular dysfunction whether due to the effect of 
metabolites, drugs or toxins, the response of low 
TmP/GFR to therapy may assist in monitoring 
these patients.
Conclusion
Renal function, glomerular as well as tubular, 
appears to be well preserved in beta-thalassaemic 
adult patients. In this study, almost all renal 
indicators that include eGFR, serum creatinine 
and urea as well as FENa, urine microalbumin, and 
ß2-microglobulin were within the recommended 
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reference ranges. Raised TRP and TmP/GFR values 
were noted in the majority of thalassaemics, studied 
reflecting an upward trend in serum phosphate and 
its consequence in increasing renal reabsorption 
of phosphate. Despite the impairment in certain 
laboratory-based renal tubular indicators in some 
patients, especially those reported in the reviewed 
literature, these beta-thalassaemics had no overt 
renal disease, and so it remains questionable 
whether such functional abnormalities would have 
any long-term effect. 
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